David Jenkinson on Muck Rack

David Jenkinson

Verified
London
As seen in: C21Media, Medium, Color Research & Application, Nature, Wiley Online Library, BMJ Open, The Drum, Inkl
mediamoocha
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with David

Contact David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma

|
By Joseph Baxter, Claudia Montiel Equihua, Jan J. Molenaar, Jamie M. Aye, Gianni Bisogno, Patricia Blanc, Willemijn B. Breunis, Julia C. Chisholm, Jacquelyn Crane, Sam Daems, Laura Danielson, Bram de Wilde, Adam D. Durbin Verified, Felipe Galvez-Cancino, Patrizia Gasparini, Birgit Geoerger, Simone Graham, Mark E. Hatley, Delphine Heenen, Christine M. Heske, Simone Hettmer, Peter Houghton, Pamela R Kearns, Charles Keller, Javed S. Khan, David M. Langenau, Geffen Lass, Leo Mascarenhas, Michael Meister, Jonathan Metts, Veronique Minard-Colin, Sapna Oberoi, Daniela Palacios, Abbe Pannucci, Seema Patel, Sheena M Patel, Silvia Pomella, Terry Rabbitts, Rossella Rota, Erin R Rudzinski, Beat W. Schäfer, Karin Straathof, Rajkumar Venkatramani, Marco Wachtel, Sara Wakeling, Zoe Walters, Sam Warburton, Brenda J. Weigel, Andrew Pearson, David Jenkinson Verified, Janet Shipley, Michela Casanova, Innovative Therapies, Bass Hassan, Elizabeth Hookham, Fiona Kinnis, Corinne Mary Linardic, John Jack Shern
| Nature Verified
Abstract The third in a series of Paediatric Therapeutic Development Workshops focused on rhabdomyosarcoma. Rhabdomyosarcoma is the most common soft tissue sarcoma in children, with 90% survival for those with the lowest risk disease, but just 20–30% in children with metastatic disease. An urgent unmet need exists to develop targeted therapeutics for high-risk disease and to reduce the toxicity of treatment.
Open in Who Shared Issue with article?

Paediatric Therapeutic Development Workshop on rhabdoid tumours - British Journal of Cancer

|
By Jan J. Molenaar, Jaclyn A. Biegel, Patricia Blanc, Susan N. Chi, Sam Daems, Laura Danielson, Jarno Drost, Michael C. Frühwald, Amar Gajjar, James Geller, annie huang, Pascal D. Johann, Pamela R Kearns, Karsten Nysom, Suzanne O’Connor, Michael Ortiz, Jenny Parker, Seema Patel, Sheena M Patel, Charles Roberts, Daniel Williamson, Joanna S. Yi, Andrew Pearson, David Jenkinson Verified, Marcel Kool, Franck Bourdeaut, Innovative Therapies, Claudia Montiel Equihua, Itziar Areso, Niels E. Franke
| Nature Verified
Abstract Rhabdoid tumours (RT) are malignancies of the central nervous system, kidneys, liver and soft tissues that most commonly affect very young children with survival rates below 30% in high-risk cohorts. Treatment entails surgery, intensive chemotherapy and radiotherapy, associated with substantial short- and long-term toxicities. There is an unmet need to develop targeted therapies for RT to improve patient outcomes and mitigate the toxicities of current therapy.
Open in Who Shared Issue with article?

Prescribing of medication to prevent glucocorticoid harms in patients with Polymyalgia Rheumatica: a cross‐sectional study and two emulated target trials in the Clinical Practice Research Datalink Aurum

|
By Helen Twohig, David Jenkinson Verified, James Bailey
| Wiley Online Library Verified
Supporting Information Filename Description art70087-sup-0001-Disclosureform.pdfPDF document, 293.5 KB Disclosure Form art70087-sup-0002-Supinfo.pdfPDF document, 743 KB Data S1: Supporting Information
Open in Who Shared Issue with article?
See all 79 licensed articles (82 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified